home hero

THE MULTIPLE MYELOMA
DIFFERENCE

A case for change in patient care

THE CALL-TO-ACTION

A Janssen Oncology Initiative,
Developed with a Global Expert Collaboration Council

Collaborating For Change

Multiple myeloma. Those living with it and those treating it deserve even more.

Great scientific advancements have indeed been made, but there still remains a number of unmet needs preventing optimal care from being delivered, consistently, globally.

This needs to change. And now, it can.

Together, we have an opportunity for alignment, connectivity, and collaboration. To not only improve outcomes in multiple myeloma, but every experience with this incurable disease.

This is the Call-to-Action.

This Call-to-Action outlines high-priority unmet needs and recommended areas of focus for the global multiple myeloma community, as identified by the Collaboration Council.

THE CALL-TO-ACTION

The multiple myeloma difference

incurable

Incurable

Despite significant scientific advancements, multiple myeloma remains an incurable disease.1

Complex

Complex

The highly heterogeneous nature of multiple myeloma has required a myriad of treatment options, which all need careful selection and often combination or sequencing, specific to each patient.1 This creates complexity for healthcare teams and their patients.2

Continuous

Continuous

Multiple myeloma is characterized by cycles of response, remission, and relapse.1 It can require continuous treatment, which places a significant physical,3,4 psychological,5 and financial6 burden on everyone involved.

The Global MM Collaboration Council

incurableMEET OUR GLOBAL EXPERTS

What needs to be done

What needs to be doneDISCOVER THE UNMET NEEDS

Abbreviations & References

MM, multiple myeloma.

  1. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479-91.
  2. Hernández-Rivas J, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1.
  3. Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, et al. Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. J Natl Compr Canc Netw. 2020;18(8):1087-95.
  4. Quinn B, Ludwig H, Bailey A, Khela K, Marongiu A, Carlson KB, et al. Physical, emotional and social pain communication by patients diagnosed and living with multiple myeloma. Pain Manag. 2022;12(1):59-74.
  5. Gatopoulou X, Iraqi W, Morgan K, Helme K, Spain VA, Redfearn J, et al. The burden of a multiple myeloma diagnosis on patients and caregivers in the first year: Western European findings. Clinicoecon Outcomes Res. 2022;14:731-53.
  6. Tran D, Kamalakar R, Manthena S, Karve S. Economic burden of multiple myeloma: results from a large employer-sponsored real-world administrative claims database, 2012 to 2018. Blood. 2019;134(Supplement_1):3414.

This Call-to-Action outlines high-priority unmet needs and recommended areas of focus for the global multiple myeloma community, as identified by the Collaboration Council.

THE CALL-TO-ACTION